Archivo Médico de Camagüey (Nov 2018)
Evaluation of the quality of life in patients with esophageal cancer treated with self-expanding stent
Abstract
Background: the study of health-related quality of life in patients with inoperable esophageal cancer using self-expanding stent provides useful information for selecting the appropriate treatment option. The EORTC QLQ-C30 instrument for evaluating the patient with esophageal cancer and the EORTC QLQ-OES18 complement module allows direct exchange with the patient and predicts the impact of the disease and treatment on the patient. Objective: to perform a review and reflection on the different aspects related to the evaluation of the quality of life in cancer patients treated with self- expanding metal esophageal stent. Methods: a search was carried out in the engines Google, PUBMED, SciELO Regional, SciELO Public Health, SciELO Cuba, Biblioteca Virtual de Salud Cuba, Medline Plus, WebMD, Medscape, National Institutes of Health, National Library of Medicine GoPubMed. In the search strategy, the terms quality of life, health-related quality of life, esophageal cancer and Self-expanding esophageal stent were used. The documents were extensively evaluated and a summary document of the information collected was developed. Development: a total of 20 papers were reviewed, including the characterization of patients with esophageal cancer 4, dysphagia palliation using self-expanding esophageal stent 7, quality of life 4 specific, measurement instruments 3 and modality of combined treatments 2. Conclusions: health-related quality of life is nowadays considered one of the most important pillars in order to evaluate the impact of a given treatment on patients with a survival shorter than three months, this will generate the acquisition and updating of knowledge among the health personnel and will serve as an impetus and motivation for its implementation in a generalized way. DeCS:ESOPHAGEAL NEOPLASMS/therapy; ESOPHAGEAL NEOPLASMS/surgery; SELF EXPANDABLE METALLIC STENTS; QUALITY OF LIFE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS.